Therapeutic efficacy of Mirena in gynecologic disease
Journal of the Korean Medical Association
;
: 459-465, 2019.
Artículo
en Coreano
| WPRIM
| ID: wpr-766606
ABSTRACT
The levonorgestrel-releasing intrauterine system (LNG-IUS) was originally developed as a method of contraception and was first marketed in Finland in 1990. In Korea, the only LNG-IUS approved for non-contraceptive use is Mirena, a T-shaped device with a vertical stem containing a reservoir of 52 mg of levonorgestrel, which releases 20 µg of levonorgestrel per day. The device's strong local effects on the endometrium benefit women with gynecological conditions such as heavy menstrual bleeding, dysmenorrhea, leiomyoma, adenomyosis, and endometriosis. There is also evidence to support its role in endometrial protection during postmenopausal estrogen therapy and in the treatment of endometrial hyperplasia without atypia and, possibly, early endometrial cancer. Because of its effectiveness, safety, and high patient satisfaction, the LNG-IUS will continue to provide important benefits in women's reproductive health.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Satisfacción del Paciente
/
Levonorgestrel
/
Neoplasias Endometriales
/
Anticoncepción
/
Dismenorrea
/
Hiperplasia Endometrial
/
Endometriosis
/
Endometrio
/
Estrógenos
/
Salud Reproductiva
Límite:
Femenino
/
Humanos
País/Región como asunto:
Asia
/
Europa
Idioma:
Coreano
Revista:
Journal of the Korean Medical Association
Año:
2019
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS